Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.5% – Should You Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) was up 7.5% on Wednesday . The stock traded as high as $13.75 and last traded at $13.5570. Approximately 1,864,014 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 5,450,944 shares. The stock had previously closed at $12.61.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on NTLA shares. Citizens Jmp lifted their target price on Intellia Therapeutics from $28.00 to $30.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 28th. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada lifted their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 3rd. Robert W. Baird lifted their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, April 27th. Finally, William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $20.25.

Intellia Therapeutics Trading Up 1.9%

The firm has a market cap of $1.95 billion, a P/E ratio of -3.94 and a beta of 1.93. The firm has a 50-day simple moving average of $13.53 and a 200-day simple moving average of $11.98.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter last year, the firm earned ($1.10) EPS. Research analysts predict that Intellia Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Avidity Partners Management LP bought a new stake in Intellia Therapeutics during the 1st quarter valued at $962,000. Wellington Grp LLC boosted its position in shares of Intellia Therapeutics by 50.9% in the 1st quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock worth $594,000 after purchasing an additional 15,620 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter worth $250,000. Finally, California State Teachers Retirement System boosted its position in shares of Intellia Therapeutics by 39.6% in the 1st quarter. California State Teachers Retirement System now owns 138,259 shares of the company’s stock worth $1,772,000 after purchasing an additional 39,253 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.